For the quarter ending 2026-03-31, PXLW had $39,754K increase in cash & cash equivalents over the period. -$4,688K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) | 80,584 | -3,720 | -4,593 | -14,945 |
| Gain on sale of patents | - | 3,000 | - | - |
| Gain on sale of pwsh | -85,153 | - | - | - |
| Stock-based compensation | 355 | 659 | 755 | 1,490 |
| Depreciation and amortization | - | 2,596 | - | - |
| Reversal of uncertain tax positions | 87 | 0 | 0 | 261 |
| Depreciation and amortization | -1,979 | - | 646 | 1,401 |
| Deferred income tax expense (benefit) | - | -38 | - | - |
| Deferred income tax expense | 150 | - | -145 | 23 |
| Loss on asset disposal | -14 | -2 | 0 | -34 |
| Accounts receivable, net | 0 | -1,202 | 620 | -741 |
| Inventories | 0 | 335 | -934 | -127 |
| Prepaid expenses and other current and long-term assets, net | 470 | -1,256 | -531 | -699 |
| Accounts payable | 205 | -963 | 199 | 84 |
| Accrued current and long-term liabilities | -165 | -2,309 | -76 | -1,049 |
| Income taxes payable | 38 | 97 | -491 | 388 |
| Net cash used in operating activities | -4,583 | -6,478 | -2,860 | -11,268 |
| Proceeds from sale of pwsh, net of cash disposed of and transaction costs | 44,437 | 3,000 | - | - |
| Asset related government subsidies received | - | 0 | 0 | 754 |
| Purchases of property and equipment | 105 | 45 | 163 | 240 |
| Net cash provided by (used in) investing activities | 44,332 | 2,955 | -163 | 514 |
| Proceeds from lines of credit | - | 741 | 1,404 | - |
| Proceeds from issuance of common stock under employee equity incentive plans | 5 | 0 | 19 | 29 |
| Proceeds from issuance of common stock | - | 7,882 | - | - |
| Net proceeds from 'registered direct offering' | -1,341 | - | 0 | 1,341 |
| Net proceeds from 'at the market' equity offering | 0 | 0 | 2,394 | 558 |
| Payments on asset financings | 0 | 303 | 438 | 566 |
| Net cash provided by financing activities | 5 | 6,979 | 3,379 | 1,362 |
| Net increase (decrease) in cash and cash equivalents | 39,754 | 3,456 | 356 | -9,392 |
| Cash and cash equivalents, beginning of period | 18,067 | 14,611 | 23,647 | - |
| Cash and cash equivalents, end of period | 57,821 | 18,067 | 14,611 | - |